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Objective. The present study was to investigate the feasibility of adenovirus-mediated small interference RNA (siRNA) targeting
Toll-like receptor 4 (TLR4) gene in ameliorating lipopolysaccharide- (LPS-) induced acute lung injury (ALI). Methods. In vitro,
alveolar macrophages (AMs) were treated with Ad-siTLR4 and Ad-EFGP, respectively, for 12h, 24h, and 48h, and then with LPS
(100ng/mL)for2h,andthefunctionandexpressionofTLR4wereevaluated.In vivo,ratsreceivedintratrachealinjectionof300μL
ofnormalsaline(controlgroup),300μLofAd-EGFP(Ad-EGFPgroup),or300μLofAd-siTLR4(Ad-siTLR4group)andthenwere
intravenously treated with LPS (50mg/kg) to induce ALI. Results. Ad-siTLR4 treatment signiﬁcantly reduced TLR4 expression and
productionofproinﬂammatorycytokinesfollowingLPStreatmentboth invitroandinvivo.Signiﬁcantalleviationoftissueedema,
microvascular protein leakage, and neutrophil inﬁltration was observed in the AdsiTLR4-treated animals. Conclusion.T L R 4p l a y s
a critical role in LPS-induced ALI, and transfection of Ad-siTLR4 can eﬀectively downregulate TLR4 expression in vitro and in
vivo, accompanied by alleviation of LPS-induced lung injury. These ﬁndings suggest that TLR4 may serve as a potential target in
the treatment of ALI and RNA interfering targeting TLR4 expression represents a therapeutic strategy.
1.Introduction
Pulmonary trauma, severe infection as well as hemorrhage
can result in acute lung injury (ALI) or acute respiratory
distress syndrome (ARDS), which are common pulmonary
diseasesinhumans,especiallyinpatientsundergoingsurgery
[1–4]. Studies have conﬁrmed that lipopolysaccharide (LPS)
plays important roles in the development and progression
o fA L Io rA R D S[ 5]. Increased serum endotoxin or LPS
of Gram-negative bacteria may induce pulmonary inﬂam-
mation leading to ALI and can be applied as a predictor
of multiple organ failure (MOF), particularly during sepsis.
LPS recognition by the host receptor is a critical step
leading to the activation of signal transduction cascades in
a variety of cells in the lung [6–8]. It is widely believed
that Toll-like receptor 4 (TLR4) is required for the innate
immune response to LPS of gram-negative bacteria [9, 10].
Studies have shown that mice with TLR4 gene deletion
(TLR4−/−) (C57BL/10ScCr) [9] and mice with natural point
mutation (C3H/HeJ) in TLR4 gene [10] are unresponsive to
systemic LPS. However, the role of TLR4 in the pulmonary
inﬂammation is still debatable. Some researchers speculate
that it is LPS other than TLR4 that is directly involved
in the induction of pulmonary immune response [11].
However, Jeyaseelan et al. demonstrated that LPS-induced
CD-14-dependent and -independent (CD11b-dependent)
signaling pathways in the lung were entirely dependent
on TLR4 and that blocking TLR4 might be beneﬁcial for
lung injury caused by LPS from gram-negative pathogens
[12].
With the progression in the technology of gene therapy,
RNA interference (RNAi) mediated by small interfering
RNAs (siRNA) has emerged as a powerful tool to knock
down target gene in cells and as a gold standard in the
studies on gene function [13]. Evidence has shown that
the 21 and 22 nucleotide RNAs are able to mediate the
cleavage of target RNA [14–16]. These RNAs are termed
as siRNA, and increasing attention has been paid to the
development of new target-speciﬁc drugs. Studies have
revealed that siRNAs are involved in the degradation of
not only homologous RNAs in mammalian cells, but also
speciﬁctargetsequenceofhepatitisCvirusinlivingmiceand2 Journal of Biomedicine and Biotechnology
vascular endothelial growth factor (VEGF) gene in murine
laser-induced choroidal neovascularization (CNV) model
[17].
Since LPS recognition by TLR4 is the ﬁrst step in the
pulmonary innate immune response [18, 19], downreg-
ulating TLR4 expression or blocking its functions with
antibodies may serve as eﬀective therapeutic strategies [15,
16]. Up to now, studies on TLR4-speciﬁc blocker are seldom
reportedandsiRNAtechniqueaimingtointerferewithTLR4
expression in response to pathogen associated molecules has
been one of the promising strategies. In the present study,
we designed recombinant adenovirus expressing siRNA
targeting TLR4 gene or enhanced green ﬂuorescent protein
(EGFP) gene, which was then transfected into macrophages
in vitro and rats in vivo. Our study aimed to identify the role
ofTLR4intheLPS-inducedALIandevaluatethetherapeutic
eﬃcacy of TLR4 siRNA in ALI. We for the ﬁrst time
used siRNA targeting TLR4 (Ad-siTLR4) to downregulate
TLR4 expression in the lung for the treatment of ALI. Our
results demonstrated that transfection with Ad-siTLR4 may
be a useful approach for the treatment of TLR4-mediated
inﬂammatory response.
2.MaterialsandMethods
2.1. Construction and Identiﬁcation of pShuttleH1-siTLR4.
The siRNA targeting TLR4 gene (GenBank accession
NM 019178) was screened and tested in our previous study
[20]. Based on the sequences of adenovirus and “Tuschl”
principle, target sequence was designed and chemically syn-
thesized by United Gene Company (Shanghai, China). This
siRNAconsistedofanRNAduplexcontainingasensestrand:
5 -GAT CCC CGT CTC AGA TAT CTA GAT CTT TCA AGA
GAA GAT CTA GAT ATC TGA GAC TTT TT-3  and an
antisense strand: 5 -AGC TAA AAA GTC TCA GAT ATC
TAG ATC TTC TCT TGA AAG ATC TAG ATA TCT GAG
ACG GG-3 . There were BamH Ia n dHind III sites at the 5 
and 3  ends, respectively. After pShuttleH1 was digested by
Bgl II and Hind III (TaKaRa, Japan), target gene was cloned
into pShuttleH1 and named as pShuttleH1-siRNA. Then,
pShuttleH1-siRNA was linearized by Pme I digestion and
transformed into E. coli BJ5183 cells containing backbone
plasmidpAdEasy-1byelectroporation.Thecorrectclonewas
identiﬁed by Hind III and Nde I restriction digestion and
sequenced by United Gene Company (Shanghai, China).
2.2. Production and Identiﬁcation of Recombinant Adenovirus
Ad-siTLR4. To produce recombinant adenovirus Ad-siTLR4
(recombinant adenovirus expressing small interference RNA
of TLR4), linearized recombinant plasmid was transfected
into HEK 293 cells with Lipofectamine 2000. Plaques were
found at about 9∼14 days after transfection. To test whether
wide-type(WT)virusemergedduringtheampliﬁcation,RT-
PCR was carried out to detect the E1 region of adenovirus.
Plaque puriﬁcation and titer determination were performed
in HEK 293 cells in six-well plates. The titers of adenovirus
were measured using the 50% tissue culture infection dosage
(TCID50) method.
2.3. Ad-siTLR4 Transfection and LPS Treatment of Pulmonary
Alveolar Macrophages. Isolation and culture of rat alveolar
macrophages(AMs)werecarriedoutaspreviouslydescribed
[21]. The AMs were applied for viral infection at the multi-
plicity of infection (MOI) of 20 at 2 days after isolation. AMs
were treated with Ad-siTLR4 and Ad-EFGP (recombinant
adenovirus expressing enhanced green ﬂuorescent protein
(EGFP)), respectively, for 12h, 24h, and 48h, and then
with LPS (100ng/mL) for 2h. Cells and supernatant were
collected for western blot assay, real-time PCR assay, as well
as ELISA.
2.4. In Vivo Experiment. The current study was approved by
theAnimalCareCommitteeofSecondMilitaryMedicalUni-
versity and performed in accordance with National Institutes
of Health guidelines for animal use. Male Sprague-Dawley
(SD)ratsweighing200–250g(6-7-weekold)werepurchased
from the Shanghai Experimental Animal Center of Chinese
Academy of Sciences and housed in an SPF laboratory under
a 12/12h light/dark cycle. The establishment of ALI model
by LPS has been described previously [22]. After anesthesia
with pentobarbital sodium (60mg/kg, i.p.), rats received
intratracheal injection of 300μL of normal saline (control
group), 300μL( 3× 109 plaque-forming units (PFU)) of
Ad-EGFP (Ad-EGFP group), or 300μL( 3× 109 PFU) of
Ad-siTLR4 (Ad-siTLR4 group). Seven days later, animals in
the Ad-EGFP and Ad-siTLR4 group received intravenous
injection of LPS (5mg/kg). In the control group, normal
saline (5mg/kg) was injected intravenously and the lungs
were collected 4h later by thoracotomy. The right lung was
ﬁxed in 4% formaldehyde before routine processing and
paraﬃn embedding.
2.5. Total Protein Content in Bronchoalveolar Lavage Fluid.
Bronchoalveolar lavage ﬂuid (BALF) was obtained by can-
nulating the trachea with a needle and by infusing the lungs
ﬁvetimeswith1mLofsaline.Approximately4.0mLofBALF
was obtained from each rat and homogenized on ice in 3mL
of cold (4◦C) normal saline (0.9% NaCl) three times. The
homogenate was centrifuged at 1000×gf o r1 0m i na t4 ◦C.
The total protein concentration of BALF was determined by
using the Bradford assay (Bio-Rad, Hercules, Calif).
2.6. Analysis of Lung Injury in ALI Rat
2.6.1. Wet-to-Dry Ratio of the Lung. Pulmonary edema was
estimated by wet-to-dry ratio of the lung, a technique
commonly used for the assessment of experimental lung
injury [2]. Lungs were removed and rinsed brieﬂy in PBS.
The water on the lung was removed and then weighed as the
“wet”weight.Lungswerethendriedinanovenat200◦Cfor2
days and weighed again as the “dry” weight. Wet-to-dry ratio
was calculated as “wet” weight/“dry” weight.
2.6.2. Histological Examination of the Lung. The lungs were
ﬁxed in 4% paraformaldehyde with 1.5% picric acid in
0.16M phosphate buﬀer (pH 7.2∼7.4) overnight at 4◦C,
embedded in paraﬃn, and cut into 5-μm sections followedJournal of Biomedicine and Biotechnology 3
by hematoxylin and eosin (HE) staining for histological ex-
amination.
2.6.3. Myeloperoxidase (MPO) Assay. MPO activity was
measured as described previously [21, 23]. Upon thawing,
the lung tissues were homogenized in PBS (20mM, pH 7.4)
and centrifuged at 30 000×g for 30min. The pellet was
resuspended in fresh PBS (50mM, pH 6.0) containing 0.5%
hexadecyltrimethyl ammonium bromide. The MPO activity
of cell suspension was assayed by measuring the absorbance
spectrophotometrically at 460nm, using 0.167mg/mL O-
dianisidine hydrochloride and 0.0005% hydrogen peroxide.
One unit of MPO activity was deﬁned as the quantity of
enzymedegrading1μmolofperoxidepermin,anddatawere
expressed as units per gram of wet tissue.
2.7.Real-TimePCR. Real-timePCRwasperformedtodetect
the mRNA expression of TLR4 in the lung tissues. Total
RNA was extracted from the lung using TRIzol reagent
(Invitrogen, Carlsbad, CA). The isolated RNA was treated
with DNase I at 37◦C for 30min before reverse transcription
was performed using a high capacity cDNA archive kit
(TaKaRa, Japan). The PCR primers were as follows: 5 -CGG
GAG CTC TGA ATG CTC TCT TGC ATC TGG CTG GC-3 
(forward) and 5 -CGG GTC GAC GCC ATA CAA TTC GAC
CTG CTG-3  (reverse). The real-time PCR was performed
using the MasterMix System (Roche, Switzerland).
2.8. Western Blot Assay. The protein expression of TLR4 in
the AMs after transfection was determined by western blot
assay using Nupage 4∼12% Bis-Tris (Invitrogen, Carlsbad,
CA) as previously described [24]. Anti-TLR4 antibody was
purchased from Santa Cruz Biotechnology (Santa Cruz,
USA).
2.9. Immunohistochemistry for TLR4 in the Lung. The lungs
were ﬁxed in 4% paraformaldehyde and 1.5% picric acid
in 0.16M PBS (pH 7.2∼7.4) overnight at 4◦C. Samples
were removed and postﬁxed in the same ﬁxative for 3h
and then in 15% sucrose overnight. Transverse lung sections
(30μm) were obtained with a cryostat and processed for
immunoﬂuorescence staining. All of sections were blocked
with 2% goat serum in 0.3% Triton X-100 for 1h at
room temperature and incubated with anti-TLR4 antibody
(anti-rabbit, 1:400; Santa Cruz, USA) over two nights at
4◦C. The sections were then incubated with Cy3-conjugated
secondary antibody (1:300; Santa Cruz, USA) for 1h at
room temperature and with a mixture of FITC- and Cy3-
conjugated secondary antibodies for 1h at room tempera-
ture. Subsequently, these sections were observed under an
Olympus ﬂuorescence microscope (Olympus, Japan), and
representative images were captured.
2.10. Enzyme-Linked Immunosorbant Assay (ELISA) for
Cytokine Detection. To detect the IL-1β and TNF-α protein
levels,thecellsupernatantandBALFofratswereanalyzedby
using the ELISA kits speciﬁc for these cytokines (Peprotech,
UK). The ELISA of BAL ﬂuid was performed according to
the manufacturer’s instructions.
3. Results
3.1. LPS-Induced Increase of TLR4 Expression Was Reduced
by Ad-siTLR4 In Vitro. Before LPS induction, AMs were
transfected with Ad-siTLR4 for 12h, 24h, and 48h. Cells
transfected with Ad-EGFP served as controls. Real-time PCR
showed Ad-siTLR4 signiﬁcantly downregulated the mRNA
expression of TLR4 at 12h, 24h, and 48h after transfection
when compared with the Ad-EGFP group (Figure 1(b)).
Western blot assay showed TLR4 protein expression was also
decreased at 24h and 48h after transfection (Figure 1(a)).
Furthermore, the TLR4 expression was decreased in a time-
dependent manner following Ad-siTLR4 transfection. TLR4
signal pathway after Ad-siTLR4 transfection in vitro was also
evaluated via detecting the production of proinﬂammatory
cytokines, including TNF-α and IL-1β. Results revealed
LPS could induce the production of these cytokines in
vitro, which was associated with the upregulation of TLR4
expression (Figures 1(c) and 1(d)). Following transfection
with Ad-siTLR4, AMs presented signiﬁcantly lower level of
cytokines when compared with the Ad-EGFP group, which
was also accompanied by the down-regulation of TLR4
expression.
3.2. LPS-Induced TLR4 Expression Was Inhibited by Intratra-
cheal Injection of Ad-siTLR4 in Rats. The silencing of TLR4
gene by Ad-siTLR4 was also investigated in rats with LPS-
induced ALI. Four hours after LPS administration, the lungs
were collected for real-time PCR assay, immunoﬂuorescence
staining as well as other molecular biological detections.
Resultsshowed that TLR4 mRNA expression increased in the
Ad-EGFPgroupascomparedtothecontrolgroup.IntheAd-
siTLR4 group, the TLR4 mRNA expression was dramatically
decreased when compared with Ad-EGFP group (P<
0.05) (Figure 2(a)). Immunoﬂuorescence staining showed
the TLR4 protein expression in the lung of diﬀerent groups
wasconsistentwiththatinreal-timePCRassay(Figures 2(b),
2(c),a n d2(d)). In the Ad-EGFP group, EGFP was mainly
found in the bronchus epithelial cells and alveolar epithelial
cells after intratracheal injection (Figure 3), indicating that
the recombinant adenovirus could be delivered to the
target cells through intratracheal injection. The LPS-induced
increase of TLR4 protein expression was reduced signiﬁ-
cantly following Ad-siTLR4 transfection. Exposure to Ad-
EGFP had no eﬀect on the TLR4 expression. These ﬁndings
implyintratrachealinjectionofAd-siTLR4caninterferewith
the TLR4 mRNA transcription, and then inhibit its protein
expression.
3.3.TLR4-RelatedProinﬂammatoryCytokinesWereDecreased
after Knockdown of TLR4 Gene. Inﬂammatory cytokines,
such as TNF-α and IL-1, were shown to play key roles in
the pathophysiology of LPS-induced ALI. We measured the
levels of these cytokines in the BALF after LPS treatment.
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Figure 1: (a) Western blot assay of TLR4 following Ad-siTLR4 or
Ad-EGFP pretreatment in LPS treated AMs. (b) Real-time PCR
analysis of TLR4 mRNA expression in LPS-treated AMs. (c) and (d)
levels of TNF-α and IL-1β in the supernatant. ∗P<0.05 versus Ad-
EGFP group.
treatment in the Ad-EGFP group had markedly increased
expressions of TNF-α and IL-1. In Ad-siTLR4 group, TNF-
α and IL-1 expressions markedly decreased at 4h after LPS
treatment as compared to the Ad-EGFP group (Figure 4).
3.4. Ad-siTLR4 Targeting TLR4 Attenuated LPS-Induced ALI.
In the present study, pathological features of the lungs of
rats with LPS-induced lung injury were observed following
Ad-siTLR4treatment.Lunghistologicalexaminationshowed
that, in animals treated with saline, the lung was almost
























Figure 2: (a) mRNA level of TLR4 in the lung in control group,
Ad-EGFP group, Ad-siTLR4 group following LPS treatment. (b),
(c), and (d) represent TLR4 protein expression in the lung tissues in
control group, Ad-EGFP group, and Ad-siTLR4 group, respectively.
∗P<0.05 versus Ad-EGFP group, #P<0.05 versus control group.
White arrow shows the positive cells.
intact (Figure 5(a)). By contrast, in the Ad-EGFP group,
LPS treatment signiﬁcantly increased the exudation and
thickenedthealveolarwallsaccompaniedbyalveolusconges-
tion, hemorrhage as well as massive neutrophil inﬁltration
(Figure 5(b)).Thepathologicalchangesinthelungswerenot
obvious in the Ad-siTLR4 group (Figure 5(c)). The wet/dry
ratio of the lungs was measured to represent the extent of
lung edema. Results revealed LPS dramatically increased the
wet/dry ratio, while Ad-siTLR4 treatment markedly reduced
the lung edema when compared with the Ad-EGFP group
(Figure 5(d)). Moreover, in the Ad-EGFP group, the content
of total proteins was signiﬁcantly increased as compared
to the control group. However, treatment with Ad-siTLR4
markedly decreased the total protein content in the BALF,
indicating intratracheal injection of Ad-siTLR4 can improve
the LPS-induced microvascular leakage (Figure 5(e)). In
order to examine the leukocyte inﬁltration in response
to LPS, the lung MPO activity, an index of neutrophil
sequestration, was determined. Findings displayed there wasJournal of Biomedicine and Biotechnology 5
(a)
(b)
Figure 3: (a) and (b) represent adenovirus transfected into bron-
chus epithelial cells (a) and alveolar epithelial cells (b), respectively.
The green ﬂuorescence represents the adenovirus.
no signiﬁcant diﬀerence in the lung MPO activity between
the saline group and the Ad-siTLR4 group indicating no
obvious neutrophil inﬁltration into both the alveolar space
and the whole lung, while MPO activity in the Ad-EGFP
group was signiﬁcantly increased when compared with the
formertwogroups(Figure 5(f)).Theseobservationsindicate
that Ad-siTLR4 treatment can improve the lung injury in
response to LPS through reducing microvascular damage,
decreasing neutrophil inﬂux, and improving lung histology.
4. Discussion
Results in the present study revealed Ad-siTLR4 could
interfere with the TLR4 expression in vivo and in vitro,a n d
treatment with Ad-siTLR4 could improve the LPS-induced
ALI. To our knowledge, this study is for the ﬁrst time to
report siRNA targeting TLR4 as a therapeutic strategy for rat
ALI. Our ﬁndings showed Ad-siTLR4 targeting TLR4 could
directlyreducetheTLR4expressionafterLPStreatmentboth
in vivo and in vitro. Moreover, this treatment also attenuated
pulmonary injury by decreasing the production of proin-
ﬂammatory cytokines in the lungs and alleviating the patho-
logicalinﬂammation.Themainﬁndingsofthisstudysuggest
TLR4 plays a critical role in the LPS-induced ALI and gene
therapy targeting TLR4 may become a promising strategy in












































Figure 4: Eﬀect of Ad-siTLR4 transfection on the expression of
proinﬂammatory cytokines in the lung of ALI rats. The TNF-
α (a) and IL-1β (b) were determined by ELISA at 4h after LPS
administration.Datawereexpressedasfoldchangewhencompared
with saline-treated animals. ∗P<0.05 versus Ad-EGFP group,
#P<0.05 versus control group.
ALI or ARDS is one of clinical conditions associated with
sepsis in humans and characterized by the microvascular
protein leakage, neutrophil inﬂux, excessive production of
proinﬂammatory mediators, and poor lung function [12,
19, 25]. Infection with gram-negative bacteria may lead
to the development of sepsis syndrome as a consequence
of excessive host response to LPS in humans. Increasing
evidence demonstrates that TLR4 is required for the innate
immune response to LPS from gram-negative bacteria.
The potential mechanism of TLR4 mediating the devel-
opment of ALI involves LPS signaling transduction [26–
28]. Binding of LPS to TLR4 in conjunction with other
molecules (LBP, CD14, and MD2) is a crucial step for
initiating intracellular signal transduction that accounts for
its multiple biological eﬀects leading to ALI. Upon LPS
recognition, TLR4 interacts with its downstream MyD88
(myeloid diﬀerentiation primary response gene 88) adaptor
domain [29, 30] and activates intracellular signal molecule
including TRAF6 (TNF receptor-associated factor 6) and
IKKα, β (IκB kinase) to form a complex and phosphorylate
IκB[ 31, 32]. This phosphorylation leads to the degradation
of IκB with subsequent translocation of NF-κB, which con-
trols the expression of proinﬂammatory cytokines including
IL-1β,a n dT N F - α [33]. Based on well-known LPS/TLR4
signal transduction pathway, the proinﬂammatory cytokines
TNF-α and IL-1β were employed to assess the cytokine
response following LPS exposure. Our results also demon-
strated systemic administration of LPS led to the signiﬁcant



































































































Figure 5: Eﬀects of Ad-siTLR4 on LPS-induced ALI. Lungs
were collected at 4h after injection of normal saline or LPS for
histological examination (a, b, c). Sections were stained with hema-
toxylin-eosin. Magniﬁcation: ×100 Wet/Dry ratio (d), total protein
content in BALF (e) as well as MPO activity (f) were measured
to determine the lung edema, microvascular permeability, and
neutrophil sequestration, respectively. ∗P<0.05 versus Ad-EGFP
group, #P<0.05 versus control group.
IL-1β and TNF-α, which were markedly reduced following
pretreatment with Ad-siTLR4 targeting TLR4 in vitro and in
vivo.Inordertoconﬁrmthatthisinﬂammatoryresponsewas
provoked by LPS instead of Ad-siTLR4 itself, animals were
also injected with Ad-siTLR4 as controls. When compared
with LPS administration alone, Ad-siTLR4 injection alone
could not evoke the abovementioned immune inﬂammatory
response, indicating that LPS evoked these inﬂammatory
pathological changes.
The role of TLR4 in the development of ALI is still
controversial. A study demonstrated that factors other than
TLR4 were involved in the secretion of TNF-α and MIP-2
in the lungs in response to inhaled LPS and the authors
postulated that this response was due to low levels of
contamination by the E. coli LPS [11]. In addition, another
study reported that TLR4 played a role in lung inﬂammation
induced by hemorrhage following LPS injection, but the
authors neither examined the cytokine proﬁles (such as
TNF-α) nor determined the lung histopathology [34]. This
possibility is unlikely since Jeyaseelan et al. [12] showed
that TLR4 is solely responsible for the induction of ALI
via activation of NF-κB with subsequent production of
cytokines. In present study, Ad-siTLR4 was prepared for the
treatment of LPS-induced ALI. Our results conﬁrmed that
upregulation of TNF-α and IL-1β was dependent on TLR4
overexpression as a response to LPS. Thereby, TLR4 may
be a valuable target in the immunotherapy of acute lung
inﬂammation due to endotoxins. Our results also indicated
markedly mild inﬂammatory response including signiﬁ-
cantly low levels of TNF-α and IL-1β in the lung, and low
totalproteinlevelinBALF,decreasedMPOactivity,aswellas
reduced wet/dry ratio following Ad-siTLR4 treatment when
compared with LPS group. Furthermore, when compared
with control group, no signiﬁcant changes were found in the
lung histopathology in the Ad-siTLR4 group. These ﬁndings
imply TLR4 modulation in ALI in response to LPS may have
therapeutic value.
IntheapplicationofsiRNA,thespeciﬁcity,eﬃciency,and
stability of siRNA in target cells should be considered [35].
Therefore, to successfully achieve gene silencing, carefully
designed siRNA and eﬀective delivery to the target lung
cells are paramount. In the present study, 21 duplexes with
a 19-base central double-stranded region and terminal 2-
base 3  overhangs were applied. This siRNA mimics the
naturally occurring molecules produced by dicer processing
invivo andcanpreventoﬀ-targeteﬀects.Ithasbeenreported
that siRNA mediated down-regulation of gene expression
is transient and can last for only 3∼5d a y sin vitro.O u r
results demonstrated that the adenovirus carrying siRNA
targeting TLR4 could exert therapeutic eﬀect for at least
7d a y sin vivo and the gene silencing lasts for at least
48h in vitro. To obtain high performance of interference,
adenovirus expressing siRNA was delivered to the lungs
via intratracheal instillation to directly colonize in target
cells of lung, with prolonged therapeutic eﬃcacy. The
presence of EGFP showed that adenovirus-vector system
was delivered to the bronchoepithelial cells, pulmonary
alveoli epithelial cells as well as macrophages at 7 days after
instillation indicating that the vector was integrated into the
target cells with relatively long expression. In vitro,d o w n -
regulation of TLR4 expression by Ad-siTLR4 was shown
in the pulmonary macrophages following LPS treatment.
Western blot assay of collected cells also exhibited decreased
TLR4 expression in a time-dependent manner. Moreover, we
showed a marked reduction of TLR4 expression followingJournal of Biomedicine and Biotechnology 7
Ad-siTLR4 accompanied by compromised TLR4 functions
which were demonstrated by the reduced production of
TNF-α and IL-1β following LPS stimulation in vitro. These
results demonstrated that the siRNA targeting TLR4 gene
was expressed by the adenovirus knock-down TLR4 gene
eﬃciently.
In summary, our results demonstrate that TLR4 medi-
ates the LPS induced ALI in a rat model. Furthermore,
delivering siRNA targeting TLR4 to target cells in the
lung exhibits therapeutic eﬀect on ALI. Collectively, the
ﬁndings in the present study suggest TLR4 is an attractive
target for immunomodulation and support that inhibiting
TLR4 expression by using siRNA is a promising therapeutic
strategy to minimize ALI.
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